



Clinical Treatment Scenarios: Vitiligo Pathogenesis and the Role of JAK Inhibition

Clinical Brief #2 – Switching Therapy in a Patient With Vitiligo

References

Tweet 2 References:

Hu Z, Wang T. Beyond skin white spots: vitiligo and associated comorbidities. *Front Med (Lausanne)*. 2023;10:1072837. doi:10.3389/fmed.2023.1072837

Additional References:

Grimes PE, Miller MM. Vitiligo: patient stories, self-esteem, and the psychological burden of disease. *Int J Womens Dermatol*. 2018;4(1):32-37. doi:10.1016/j.ijwd.2017.11.005

Hamzavi IH, Bibeau K, Grimes P, et al. Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study. *Br J Dermatol*. 2023;189(5):569-577. doi:10.1093/bjd/ljad245

OPZELURA™ (ruxolitinib). Prescribing information. Incyte Corporation. Approved 2011. Revised January 2023.

<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215309>

Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. *N Engl J Med*. 2022;387(16):1445-1455. doi:10.1056/NEJMoa2118828

Shourick J, Ahmed M, Seneschal J, et al. Development of a shared decision-making tool in vitiligo: an international study. *Br J Dermatol*. 2021;185(4):787-796. doi:10.1111/bjd.20137



BSA, body surface area
CI, confidence interval
F-VASI, Facial Vitiligo Area Scoring Index
HCP, healthcare provider
MetS, metabolic syndrome
NBUVB, narrowband ultraviolet B
QoL, quality of life
TSH, thyroid stimulating hormone
TVASI, Total Vitiligo Area Scoring Index
VASI50, Vitiligo Area Scoring Index improvement of 50%
w/, with